Evidence map›Paper›PMID 39535903›Full record

ArticleClinical science (London, England : 1979)2024

Protective effect of mesenchymal stromal cells in diabetic nephropathy: the In vitro and In vivo role of the M-Sec-tunneling nanotubes.

Federica Barutta, Beatrice Corbetta, Stefania Bellini, Roberto Gambino, Stefania Bruno, Shunsuke Kimura, Koji Hase, Hiroshi Ohno, Gabriella Gruden

Abstract read
In one paragraph

Article in Clinical science (London, England : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Federica BaruttaDepartment of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0001-9319-5123
Beatrice CorbettaDepartment of Medical Sciences, University of Turin, Turin, Italy.
Stefania BelliniDepartment of Medical Sciences, University of Turin, Turin, Italy.
Roberto GambinoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Stefania BrunoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Shunsuke KimuraDivision of Biochemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Koji HaseDivision of Biochemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Hiroshi OhnoLaboratory for Intestinal Ecosystem, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Gabriella GrudenDepartment of Medical Sciences, University of Turin, Turin, Italy.

Funding

European Foundation for the Study of Diabetes (EFSD)Ferrero FoundationItalian Ministry for Education, University and ResearchNovo Nordisk Fonden (NNF)Turin University (ex. 60% grant)
6 · The paper itself

Abstract

Mitochondrial dysfunction plays an important role in the development of podocyte injury in diabetic nephropathy (DN). Tunnelling nanotubes (TNTs) are long channels that connect cells and allow organelle exchange. Mesenchymal stromal cells (MSCs) can transfer mitochondria to other cells through the M-Sec-TNTs system. However, it remains unexplored whether MSCs can form heterotypic TNTs with podocytes, thereby enabling the replacement of diabetes-damaged mitochondria. In this study, we analysed TNT formation, mitochondrial transfer, and markers of cell injury in podocytes that were pre-exposed to diabetes-related insults and then co-cultured with diabetic or non-diabetic MSCs. Furthermore, to assess the in vivo relevance, we treated DN mice with exogenous MSCs, either expressing or lacking M-Sec, carrying fluorescent-tagged mitochondria. MSCs formed heterotypic TNTs with podocytes, allowing mitochondrial transfer, via a M-Sec-dependent mechanism. This ameliorated mitochondrial function, nephrin expression, and reduced apoptosis in recipient podocytes. However, MSCs isolated from diabetic mice failed to confer cytoprotection due to Miro-1 down-regulation. In experimental DN, treatment with exogenous MSCs significantly improved DN, but no benefit was observed in mice treated with MSCs lacking M-Sec. Mitochondrial transfer from exogenous MSCs to podocytes occurred in vivo in a M-Sec-dependent manner. These findings demonstrate that the M-Sec-TNT-mediated transfer of mitochondria from healthy MSCs to diabetes-injured podocytes can ameliorate podocyte damage. Moreover, M-Sec expression in exogenous MSCs is essential for providing renoprotection in vivo in experimental DN.

Indexed as

Diabetes Mellitus, ExperimentalDiabetic NephropathiesMesenchymal Stem CellsMitochondriaNanotubesPodocytesAnimalsApoptosisCell CommunicationCells, CulturedCoculture TechniquesMaleMesenchymal Stem Cell TransplantationMiceMice, Inbred C57BLalbuminuriadiabetic nephropathymesenchymal stem cellmitochondriapodocytestunneling nanotubes

Identifiers

PMID39535903
PMCPMC11609313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.